全文获取类型
收费全文 | 34939篇 |
免费 | 1895篇 |
国内免费 | 207篇 |
专业分类
耳鼻咽喉 | 439篇 |
儿科学 | 534篇 |
妇产科学 | 433篇 |
基础医学 | 4631篇 |
口腔科学 | 994篇 |
临床医学 | 2275篇 |
内科学 | 9179篇 |
皮肤病学 | 528篇 |
神经病学 | 2419篇 |
特种医学 | 1230篇 |
外科学 | 6055篇 |
综合类 | 155篇 |
一般理论 | 3篇 |
预防医学 | 1051篇 |
眼科学 | 652篇 |
药学 | 2266篇 |
中国医学 | 85篇 |
肿瘤学 | 4112篇 |
出版年
2023年 | 163篇 |
2022年 | 130篇 |
2021年 | 607篇 |
2020年 | 358篇 |
2019年 | 530篇 |
2018年 | 690篇 |
2017年 | 546篇 |
2016年 | 671篇 |
2015年 | 684篇 |
2014年 | 876篇 |
2013年 | 1082篇 |
2012年 | 1717篇 |
2011年 | 1888篇 |
2010年 | 1076篇 |
2009年 | 919篇 |
2008年 | 1708篇 |
2007年 | 1896篇 |
2006年 | 1820篇 |
2005年 | 1854篇 |
2004年 | 1814篇 |
2003年 | 1792篇 |
2002年 | 1678篇 |
2001年 | 991篇 |
2000年 | 996篇 |
1999年 | 966篇 |
1998年 | 447篇 |
1997年 | 325篇 |
1996年 | 341篇 |
1995年 | 281篇 |
1994年 | 264篇 |
1993年 | 248篇 |
1992年 | 736篇 |
1991年 | 665篇 |
1990年 | 615篇 |
1989年 | 683篇 |
1988年 | 592篇 |
1987年 | 545篇 |
1986年 | 541篇 |
1985年 | 501篇 |
1984年 | 331篇 |
1983年 | 263篇 |
1982年 | 152篇 |
1981年 | 123篇 |
1980年 | 136篇 |
1979年 | 229篇 |
1978年 | 188篇 |
1977年 | 149篇 |
1974年 | 118篇 |
1971年 | 122篇 |
1969年 | 127篇 |
排序方式: 共有10000条查询结果,搜索用时 187 毫秒
1.
2.
Mamiko Onuki Koji Matsumoto Takashi Iwata Kasumi Yamamoto Yoichi Aoki Shoji Maenohara Naotake Tsuda Shoji Kamiura Kazuhiro Takehara Koji Horie Nobutaka Tasaka Hideaki Yahata Yuji Takei Yoichi Aoki Hisamori Kato Takeshi Motohara Keiichiro Nakamura Mitsuya Ishikawa Tatsuya Kato Hiroyuki Yoshida Noriomi Matsumura Hidekatsu Nakai Shogo Shigeta Fumiaki Takahashi Kiichiro Noda Nobuo Yaegashi Hiroyuki Yoshikawa 《Cancer science》2020,111(7):2546-2557
To obtain baseline data for cervical cancer prevention in Japan, we analyzed human papillomavirus (HPV) data from 5045 Japanese women aged less than 40 years and diagnosed with cervical abnormalities at 21 hospitals during 2012‐2017. These included cervical intraepithelial neoplasia grade 1 (CIN1, n = 573), CIN2‐3 (n = 3219), adenocarcinoma in situ (AIS, n = 123), and invasive cervical cancer (ICC, n = 1130). The Roche Linear Array was used for HPV genotyping. The HPV type‐specific relative contributions (RCs) were estimated by adding multiple infections to single types in accordance with proportional weighting attributions. Based on the comparison of type‐specific RCs between CIN1 and CIN2‐3/AIS/ICC (CIN2+), RC ratios were calculated to estimate type‐specific risks for progression to CIN2+. Human papillomavirus DNA was detected in 85.5% of CIN1, 95.7% of CIN2‐3/AIS, and 91.2% of ICC. Multiple infections decreased with disease severity: 42.9% in CIN1, 40.4% in CIN2‐3/AIS, and 23.7% in ICC (P < .0001). The relative risk for progression to CIN2+ was highest for HPV16 (RC ratio 3.78, 95% confidence interval [CI] 3.01‐4.98), followed by HPV31 (2.51, 1.54‐5.24), HPV18 (2.43, 1.59‐4.32), HPV35 (1.56, 0.43‐8.36), HPV33 (1.01, 0.49‐3.31), HPV52 (0.99, 0.76‐1.33), and HPV58 (0.97, 0.75‐1.32). The relative risk of disease progression was 1.87 (95% CI, 1.71‐2.05) for HPV16/18/31/33/35/45/52/58, but only 0.17 (95% CI, 0.14‐0.22) for HPV39/51/56/59/66/68. Human papillomavirus 16/18/31/33/45/52/58/6/11 included in a 9‐valent vaccine contributed to 89.7% (95% CI, 88.7‐90.7) of CIN2‐3/AIS and 93.8% (95% CI, 92.4‐95.3) of ICC. In conclusion, our data support the Japanese guidelines that recommend discriminating HPV16/18/31/33/35/45/52/58 genotypes for CIN management. The 9‐valent vaccine is estimated to provide over 90% protection against ICC in young Japanese women. 相似文献
3.
Kiran Naqvi MD Elias Jabbour MD Jeffrey Skinner BS MHA Kristin Anderson BS Sara Dellasala BS Musa Yilmaz MD Alessandra Ferrajoli MD Prithviraj Bose MD Philip Thompson MBBS Yesid Alvarado MD Nitin Jain MBBS Koichi Takahashi MD Jan Burger MD Zeev Estrov MD Gautam Borthakur MBBS Naveen Pemmaraju MD Shilpa Paul Pharm D Jorge Cortes MD Hagop M. Kantarjian MD 《Cancer》2020,126(1):67-75
4.
5.
6.
Hirokazu Miki Shingen Nakamura Masahiro Oura Hirofumi Hamano Kenji Ikuta Naoto Okada Yasunobu Okamoto Kimiko Sogabe Mamiko Takahashi Masami Iwasa Kengo Udaka Takeshi Harada Kiyoe Kurahashi Shiro Fujii Sumiko Yoshida Kumiko Kagawa Itsuro Endo Ken-ichi Aihara Masahiro Abe 《British journal of haematology》2019,186(2):355-358
7.
8.
ObjectivesEosinophilic otitis media (EOM) is an intractable otitis media mostly associated with bronchial asthma. Dupilumab, an anti-interleukin (IL)-4 receptor (R)α, is effective and has been approved for use in patients with moderate to severe bronchial asthma, atopic dermatitis and chronic rhinosinusitis with nasal polyposis, whose diseases are not controlled by previous treatments including other molecular targeted drugs. We aimed to assess efficacy of dupilumab in three EOM patients with associated bronchial asthma, who were poor responders to previous topical and systemic corticosteroid therapy and molecular targeted therapies.Patients and methodsThree patients with severe, refractory EOM (two with a granulation type) associated with bronchial asthma received dupilumab as add-on therapy for at least 6 months. The efficacy of dupilumab therapy was evaluated using severity scores, symptom scores, hearing acuities, temporal bone computed tomography (CT) scores, and surrogate markers before and after therapy.ResultsSeverity scores in all patients were dramatically reduced to 2 points or less (full score: 16 points) after initiation of therapy. Air conduction hearing levels were improved in all patients. Temporal bone CT scores in two patients were reduced, and serum IgE levels in all three patients also decreased following therapy.ConclusionWe provide the first report that add-on dupilumab therapy was effective in patients with severe, refractory EOM who did not respond to the treatments including other molecular targeted therapy. Patients with severe middle ear mucosal change may benefit particularly from dupilumab therapy. 相似文献
9.
10.
Yang Liu Yoshifumi Baba Takatsugu Ishimoto Hiroyasu Tsutsuki Tianli Zhang Daichi Nomoto Kazuo Okadome Kensuke Yamamura Kazuto Harada Kojiro Eto Yukiharu Hiyoshi Masaaki Iwatsuki Yohei Nagai Shiro Iwagami Yuji Miyamoto Naoya Yoshida Yoshihiro Komohara Masaki Ohmuraya Xiaoming Wang Jaffer A. Ajani Tomohiro Sawa Hideo Baba 《British journal of cancer》2021,124(5):963
Background Fusobacterium nucleatum (F. nucleatum) is a gut microbe implicated in gastrointestinal tumorigenesis. Predicting the chemotherapeutic response is critical to developing personalised therapeutic strategies for oesophageal cancer patients. The present study investigated the relationship between F. nucleatum and chemotherapeutic resistance in oesophageal squamous cell carcinoma (ESCC).Methods We examined the relationship between F. nucleatum and chemotherapy response in 120 ESCC resected specimens and 30 pre-treatment biopsy specimens. In vitro studies using ESCC cell lines and co-culture assays further uncovered the mechanism underlying chemotherapeutic resistance.Results ESCC patients with F. nucleatum infection displayed lesser chemotherapeutic response. The infiltration and subsistence of F. nucleatum in the ESCC cells were observed by transmission electron microscopy and laser scanning confocal microscopy. We also observed that F. nucleatum modulates the endogenous LC3 and ATG7 expression, as well as autophagosome formation to induce chemoresistance against 5-FU, CDDP, and Docetaxel. ATG7 knockdown resulted in reversal of F. nucleatum-induced chemoresistance. In addition, immunohistochemical studies confirmed the correlation between F. nucleatum infection and ATG7 expression in 284 ESCC specimens.Conclusions F. nucleatum confers chemoresistance to ESCC cells by modulating autophagy. These findings suggest that targeting F. nucleatum, during chemotherapy, could result in variable therapeutic outcomes for ESCC patients.Subject terms: Tumour biomarkers, Oesophageal cancer 相似文献